fda tirzepatide update today approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide Update: On December 19th

Take Charge of Your Health Semaglutide is more than just a weight loss or diabetes medicationits a powerful tool for enhancing cardiovascular health

Build a complete medication history you can share with your doctor

Common Side Effects of GLP-1 Agonists While GLP-1 agonists are generally well-tolerated, some individuals may experience side effects, especially during the initial stages of treatment

The doctor may recommend continuing the current dose for a bit longer, increasing the dose, or considering alternative treatment options if semaglutide does not seem to be effective for that individual

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials